Expertise in
2
conditions

Owen R. Pearson

Port Talbot, WLS, GB 
Expertise in
2
conditions
Port Talbot, WLS, GB 

Overview

Owen Pearson practices practicing medicine in Port Talbot, United Kingdom.

Mr. Pearson is highly rated in 2 conditions, according to our data. His clinical expertise encompasses Multiple Sclerosis (MS), Relapsing Multiple Sclerosis (RMS), CACH Syndrome, and COVID-19.

He is actively involved in clinical research, co-authoring 35 peer reviewed articles and participating in 6 clinical trials.

Gender

Male

Locations

Port Talbot, WLS, United Kingdom
Other Locations
Swansea, WLS, United Kingdom
Cardiff, WLS, United Kingdom
Morriston, WLS, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

ChariotMS - A National (UK) Phase IIb, Multi-centre, Randomised, Double-blind, Placebo Controlled (1:1) Efficacy Trial With Cost-utility Analysis of Cladribine Tablets (3.5mg/kg Over Two Years) in People With Advanced Multiple Sclerosis. Is Cladribine Superior to Placebo in Protecting Upper Limb Function?
ChariotMS - A National (UK) Phase IIb, Multi-centre, Randomised, Double-blind, Placebo Controlled (1:1) Efficacy Trial With Cost-utility Analysis of Cladribine Tablets (3.5mg/kg Over Two Years) in People With Advanced Multiple Sclerosis. Is Cladribine Superior to Placebo in Protecting Upper Limb Function?
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2026
Intervention Type: Drug
Study Drug: Cladribine
Study Phase: Phase 2/Phase 3
Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for the Treatment of Relapsing-Remitting Multiple Sclerosis
Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for the Treatment of Relapsing-Remitting Multiple Sclerosis
Enrollment Status: Active_not_recruiting
Publish Date: August 31, 2026
Intervention Type: Drug
Study Drugs: Early Highly Effective Therapies Group, Escalation Therapies Group
Study Phase: Phase 4
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS)
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS)
Enrollment Status: Completed
Publish Date: January 07, 2026
Intervention Type: Drug
Study Drug: Tolebrutinib
Study Phase: Phase 3
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis
Enrollment Status: Completed
Publish Date: July 02, 2025
Intervention Type: Drug
Study Drug: Tolebrutinib
Study Phase: Phase 3
A Phase 3 Randomised, Double Blind, Clinical Trial Investigating the Effectiveness of Repurposed Simvastatin Compared to Placebo, in Secondary Progressive Multiple Sclerosis, in Slowing the Progression of Disability
A Phase 3 Randomised, Double Blind, Clinical Trial Investigating the Effectiveness of Repurposed Simvastatin Compared to Placebo, in Secondary Progressive Multiple Sclerosis, in Slowing the Progression of Disability
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug
Study Drug: Simvastatin
Study Phase: Phase 3
A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared With an Interferon Beta 1a (Avonex®), in Participants With Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety
A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared With an Interferon Beta 1a (Avonex®), in Participants With Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety
Enrollment Status: Terminated
Publish Date: August 05, 2021
Intervention Type: Drug
Study Phase: Phase 3
View 5 Less Clinical Trials

35 Total Publications

UK consensus on pregnancy in multiple sclerosis: An update to 'Association of British Neurologists' guidance.
UK consensus on pregnancy in multiple sclerosis: An update to 'Association of British Neurologists' guidance.
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: July 03, 2026

Frequently Asked Questions about Owen R. Pearson

Is Owen R. Pearson a top-rated expert for Multiple Sclerosis (MS)?

MediFind is an objective health platform that identifies experts based on real-world data. Owen R. Pearson is classified as an Distinguished expert for Multiple Sclerosis (MS), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Owen R. Pearson participate in research or clinical trials?

Yes. Owen R. Pearson has published 35 articles and abstracts on conditions like Multiple Sclerosis (MS). You can view a list of Owen R. Pearson's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Pearson's expertise for a condition
ConditionClose
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile